The EMBRACE Study The EMBRACE Study

Last updated: December 18, 2024
Sponsor: University of Aberdeen
Overall Status: Active - Recruiting

Phase

N/A

Condition

Circulation Disorders

Cancer

Breast Cancer

Treatment

N/A

Clinical Study ID

NCT04467411
2-049-18
  • Ages > 18
  • Female
  • Accepts Healthy Volunteers

Study Summary

Cardiomyopathy is a condition that affects the heart muscle, whereby it becomes enlarged, thick or rigid. When the heart muscle becomes involved, it affects the pumping action of the heart. This condition can affect as many as 10% of all patients after undergoing anthracycline cancer drug therapy and unfortunately carries the worst prognosis of all cardiomyopathies. To date, there is no effective intervention that will prevent a patient from developing this condition. The research conducted will look to see if an energy imbalance in the heart predates the onset of detrimental changes to the pumping function of the heart, if this is detected then we can act earlier to prevent the pumping function deteriorating.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • A patient who has been diagnosed with breast cancer and has been scheduled for afirst cycle of anthracycline therapy.

  • Participant who is willing and able to give informed consent for participation inthe study.

  • Healthy (gender and age matched) volunteers willing to give informed consent forparticipation in the study.

Exclusion

Exclusion Criteria:

  • Contraindication to magnetic resonance scanning such as an implantable cardiacdevice.

Study Design

Total Participants: 70
Study Start date:
February 01, 2020
Estimated Completion Date:
August 30, 2030

Study Description

There is emerging cellular and experimental evidence that cardiac energetic status is reduced after anthracycline treatment, however, this has not been tested in the human heart. The researchers hypothesize that cardiac energetic status is reduced in the human heart after administration of anthracycline therapy in breast cancer patients, inline with the evidence available from all other types of cardiomyopathies. The researchers propose to use in vivo 31Phosphorus cardiac spectroscopy to measure the cardiac energetic status at the beginning and at the end of the cycles of chemotherapy in the hearts of breast cancer patients who are administered epirubicin (the most modern anthracycline to date) and compare this with the cardiac energetic status of age and gender matched healthy controls. Further, the researchers wish to explore if the myopathy-induced effect of anthracyclines extends to the skeletal muscle as well, by examining skeletal muscle biopsies in these patients.

Connect with a study center

  • Cardiovascular Research Facility

    Aberdeen, Aberdeenshire AB25 2ZD
    United Kingdom

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.